POORLY DIFFERENTIATED THYROID CARCINOMA
Clinical trials for POORLY DIFFERENTIATED THYROID CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new POORLY DIFFERENTIATED THYROID CARCINOMA trials appear
Sign up with your email to follow new studies for POORLY DIFFERENTIATED THYROID CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough thyroid cancers: drug combo trial launches
Disease control Recruiting nowThis study tests two drugs, sacituzumab tirumotecan and tislelizumab, in people with advanced thyroid cancer that has stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or help people live longer. About 94 adults with three types of har…
Matched conditions: POORLY DIFFERENTIATED THYROID CARCINOMA
Phase: NA • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Immune-Boosting drug could help fight High-Risk thyroid cancer before surgery
Disease control Recruiting nowThis phase 2 trial is testing whether giving the drug pembrolizumab before thyroid surgery can help the immune system attack high-risk differentiated thyroid cancer. About 25 adults with a high chance of cancer returning will receive two doses of pembrolizumab before their thyroi…
Matched conditions: POORLY DIFFERENTIATED THYROID CARCINOMA
Phase: PHASE2 • Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New radioactive drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, [177Lu]Lu-AKIR001, in 15 adults with advanced solid tumors (like thyroid, head and neck, cervical, vulvar, or lung cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and sid…
Matched conditions: POORLY DIFFERENTIATED THYROID CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Karolinska University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail targets tough thyroid cancers
Disease control Recruiting nowThis phase II trial tests a combination of two drugs—MRG003 and pucotenlimab—in 60 people with a rare and aggressive form of thyroid cancer that cannot be removed by surgery. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the d…
Matched conditions: POORLY DIFFERENTIATED THYROID CARCINOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC